May 07, 2026

Not All Lung Bacteria Are the Enemy

Cross-disease meta-analysis also found modest associations with lung function, though findings varied by disease type

Conexiant

May 05, 2026

Smartwatch May Track AD Status in Children

Wearable-derived scratching measures align with disease activity and short-term treatment response in pediatric patients with atopic dermatitis.

Conexiant

May 05, 2026

Low Follow-Up After Behavioral ED Care

Follow-up occurred after fewer than 15% of mental health ED visits and about 11% of substance use–related visits in Washington Medicaid claims.

Conexiant

May 05, 2026

AAP Updates Pediatric Office Emergency Readiness

Guidance addresses office readiness, recommended equipment and medications, and team communication processes for infrequent but high-acuity emergencies.

Conexiant

May 04, 2026

FDA Expands ASCENIV Pediatric Use

Label change follows completion of required pediatric evaluation and updates prior age restrictions for treatment eligibility.

Conexiant

April 29, 2026

FDA Monthly Preview: Key May Decisions to Watch

Several FDA decisions across multiple specialties are expected this month.

Conexiant

April 28, 2026

FDA Clears Breztri for Asthma Use

Single-inhaler triple therapy improved lung function vs dual therapy in phase 3 trials and showed rapid onset without new safety signals.

Conexiant

April 24, 2026

Dupilumab Gains Pediatric CSU Approval

Targets type 2 inflammation in a population with limited treatment options

Conexiant

April 22, 2026

Tzield Approval Expands to Younger Patients

First disease-modifying option available for children as young as 1 year with stage 2 type 1 diabetes

Conexiant

April 20, 2026

FDA Reshapes Drug Testing Approach

The agency outlined early regulatory actions supporting nonanimal methods, including draft guidance, artificial intelligence tools, and expanded use of human-relevant data models.

Conexiant